Novo Integrated Sciences reported financial results for the fiscal year ended August 31, 2024. The company's net loss widened to $16,128,570, compared to $13,269,444 in the previous year. Revenue increased to $13,294,357 from $12,572,019 year-over-year, with healthcare services contributing $8,297,530 and product sales $4,918,577.The company's operating loss expanded to $10,076,298 from $8,553,162 in fiscal 2023. Interest expenses rose to $652,398 from $360,571 the previous year. Total assets decreased to $32,141,276 as of August 31, 2024, compared to $35,563,047 at the end of fiscal 2023.Novo Integrated Sciences faced challenges in its business segments, with healthcare services reporting an operating loss of $397,316. The company's product sales segment also experienced difficulties. Management did not provide specific guidance for the upcoming fiscal year but continues to focus on its healthcare services and product sales divisions.

Novo Integrated Sciences reported financial results for the fiscal year ended August 31, 2024. The company's net loss widened to $16,128,570, compared to $13,269,444 in the previous year. Revenue increased to $13,294,357 from $12,572,019 year-over-year, with healthcare services contributing $8,297,530 and product sales $4,918,577.The company's operating loss expanded to $10,076,298 from $8,553,162 in fiscal 2023. Interest expenses rose to $652,398 from $360,571 the previous year. Total assets decreased to $32,141,276 as of August 31, 2024, compared to $35,563,047 at the end of fiscal 2023.Novo Integrated Sciences faced challenges in its business segments, with healthcare services reporting an operating loss of $397,316. The company's product sales segment also experienced difficulties. Management did not provide specific guidance for the upcoming fiscal year but continues to focus on its healthcare services and product sales divisions.